Posted by Michael Wonder on 16 Sep 2019
Verrica Pharmaceuticals submits new drug application to U.S. FDA for VP-102 for the treatment of molluscum contagiosum
16 September 2019 - No FDA approved treatments are currently available for this highly contagious, primarily paediatric, viral skin infection affecting an estimated 6 million people in the United States.
Verrica Pharmaceuticals today announced that it has submitted a new drug application to the U.S. FDA for VP-102 (cantharidin 0.7% topical solution), a proprietary topical therapy, for the treatment of molluscum contagiosum (molluscum).
The 505(b)(1) application is supported by the positive results from two double-blind Phase 3 trials (CAMP-1 and CAMP-2) that evaluated the safety and efficacy of VP-102 compared to placebo in patients two years of age and older diagnosed with molluscum.
